NDA 022231 · Mallinckrodt Ireland
Terlivaz
Terlipressin Acetate · Intravenous · Vasopressin Receptor Agonist
NovelPriority reviewOrphanCDER novel approval, Sep 14, 2022: To improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function
Last checked: Nov 20, 2026Latest source record: Jun 10, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2022
Sep 14, 2022
Approved uses
1
Original approval plus efficacy supplements
Registered trials
97
26 Phase 3, 5 recruiting
FAERS reports
331
299 serious, 95 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SERIOUS OR FATAL RESPIRATORY FAILURE TERLIVAZ may cause serious or fatal respiratory failure. Patients with volume overload or with acute-on-chronic liver failure (ACLF) Grade 3 are at increased risk [see References (15) ]. Assess oxygenation saturation (e.g., SpO 2 ) before initiating TERLIVAZ. Do not initiate TERLIVAZ in patients experiencing hypoxia (e.g., SpO 2 <90%) until oxygenation levels improve. Monitor patients for hypoxia using continuous pulse oximetry during treatment and discontinue TERLIVAZ if SpO 2 decreases below 90% [see Dosage and Administration (2.1) , Contraindications (4) , and Warnings and Precautions (5.1) ]. WARNING: SERIOUS OR FATAL RESPIRATORY FAILURE TERLIVAZ may cause serious or fatal respiratory failure. Patients with volume overload or with ACLF Grade 3 are at increased risk. Assess oxygenation saturation (e.g., SpO 2 ) before initiating TERLIVAZ....
What it is approved for
From the label in effect Oct 23, 2026.
TERLIVAZ is indicated to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function. Limitation of Use Patients with a serum creatinine >5 mg/dL are unlikely to experience benefit. TERLIVAZ is a vasopressin receptor agonist indicated to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function. ( 1 ) Limitation of Use Patients with a serum creatinine >5 mg/dL are unlikely to experience benefit. ( 1 )
Mechanism: Terlipressin is a synthetic vasopressin analogue with twice the selectivity for vasopressin V 1 receptors versus V 2 receptors. Terlipressin acts as both a prodrug for lysine-vasopressin, as well as having pharmacologic activity on its own. Terlipressin is thought to increase renal blood flow in patients with hepatorenal syndrome by reducing portal hypertension and blood circulation in portal vessels and increasing effective arterial volume and mean arterial pressure (MAP).
Therapeutic areas: Rare and genetic disease · Kidney and urology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 14, 2022 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
1 products under this application
- TERLIVAZ · TERLIPRESSIN ACETATE EQ 0.85MG BASE/VIAL · POWDER, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Terlipressin" as an intervention, any sponsor and status, largest first.
Vanderbilt University Medical CenterAcademic, hospital or other
NCT02726620 · 22,435 participants · Start Jan 5, 2017 · Primary completion Dec 31, 2017
Drug: Propofol; Sevoflurane and 32 more · For: Hypotension
Sites: Nashville, Tennessee
- Comparison of Terlipressin, Somatostatin, and Octreotide for Control of Variceal BleedingPivotal-lookingCompleted
Korea UniversityAcademic, hospital or other
NCT00966355 · 1,034 participants · Start Sep 2006 · Primary completion May 2010
Drug: Terlipressin; Somatostatin and 1 more · For: Variceal Bleeding, Cirrhosis
Sites: Seoul, South Korea
- Continuos Terlipressin Infusion in Septic ShockPivotal-lookingStatus unknown
First Affiliated Hospital, Sun Yat-Sen UniversityAcademic, hospital or other
NCT01697410 · 1,000 participants (planned) · Start Jan 2013 · Primary completion Jan 2016
Drug: Terlipressin; Norepinephrine · For: Septic Shock
Sites: Guangzhou, China
- The Safety & Efficacy of Terlipressin vs Octreotide for the Control of Variceal BleedPivotal-lookingCompleted
Aga Khan UniversityAcademic, hospital or other
NCT00534677 · 320 participants · Start May 2004
Drug: Terlipressin; Octreotide · For: Portal Hypertension; Cirrhosis; Hematemesis and 1 more
Sites: Karachi, Pakistan
- ACid Tranexamic or Terlipressin for Initial Emergency Treatment of Mild to seVere hEmoptysis: a Randomized Trial.Pivotal-lookingCompleted
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT04961528 · 315 participants · Start Mar 27, 2022 · Primary completion Dec 28, 2025
Drug: Tranexamic Acid 500 MG; Terlipressin and 1 more · For: Hemoptysis
Sites: Paris, France
- Comparison of Bolus Versus Continuous Infusion of Terlipressin Cirrhotic Patients With Septic Shock.Pivotal-lookingStatus unknown
Institute of Liver and Biliary Sciences, IndiaAcademic, hospital or other
NCT04819568 · 310 participants (planned) · Start Jun 25, 2021 · Primary completion Mar 19, 2022
Drug: Terlipressin · For: Liver Cirrhosis
Sites: New Delhi, India
- Study To Confirm Efficacy and Safety of Terlipressin in Hepatorenal Syndrome (HRS) Type 1Pivotal-lookingCompleted
MallinckrodtIndustry
NCT02770716 · 300 participants · Start Jul 13, 2016 · Primary completion Jul 24, 2019
Drug: Terlipressin · For: Hepatorenal Syndrome
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 64 sites in all
- Efficacy and Safety of Hemoperfusion or Plasma Exchange Compared to Standard Medical Therapy in Patients With Acute on Chronic Liver FailurePivotal-lookingStatus unknown
Institute of Liver and Biliary Sciences, IndiaAcademic, hospital or other
NCT04013113 · 250 participants (planned) · Start Jul 9, 2019 · Primary completion Jul 31, 2020
Drug: Haemoperfusion; Standard Medical Treatment · For: Acute-On-Chronic Liver Failure
Sites: New Delhi, India
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective41
- ascites25
- diarrhoea23
- renal impairment20
- off label use18
- acute kidney injury17
- electrocardiogram qt prolonged17
- multiple organ dysfunction syndrome17
- product use in unapproved indication17
- respiratory failure17
- hepatic encephalopathy16
- toxicity to various agents16
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2005 | 5 |
| 2006 | 6 |
| 2008 | 1 |
| 2009 | 3 |
| 2010 | 3 |
| 2011 | 5 |
| 2012 | 8 |
| 2013 | 2 |
| 2014 | 14 |
| 2015 | 13 |
| 2016 | 5 |
| 2017 | 3 |
| 2018 | 9 |
| 2019 | 17 |
| 2020 | 26 |
| 2021 | 26 |
| 2022 | 29 |
| 2023 | 22 |
| 2024 | 24 |
| 2025 | 53 |
| 2026 | 56 |
Recalls
1 FDA enforcement reports for this application.
Feb 6, 2024 · Class II · Ongoing
cGMP deviations: Temperature excursion due to shipping delay from manufacturer to distributor. Affected distributor has been notified.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Beyond the Surviving Sepsis Campaign Guidelines: a systematic review of interventions affecting mortality in sepsis.
Sartini C, Landoni G, Belletti A, et al. · Panminerva Med 2024 · Systematic Review
- Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome.
Wong F, Pappas SC, Curry MP, et al. · N Engl J Med 2021 · Clinical Trial, Phase III, Multicenter Study
- THE EFFICACY AND SAFETY OF VASOPRESSORS FOR SEPTIC SHOCK PATIENTS: A SYSTEMIC REVIEW AND NETWORK META-ANALYSIS.
Jia L, Wang P, Li C, et al. · Shock 2023 · Systematic Review, Network Meta-Analysis
- Vasoactive Agents for the Management of Acute Variceal Bleeding: A Systematic Review and Meta-analysis.
Huaringa-Marcelo J, Huaman MR, Brañez-Condorena A, et al. · J Gastrointestin Liver Dis 2021 · Meta-Analysis, Systematic Review
- Vasopressors for shock.
Müllner M, Urbanek B, Havel C, et al. · Cochrane Database Syst Rev 2004 · Systematic Review
- Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study.
Cavallin M, Piano S, Romano A, et al. · Hepatology 2016 · Comparative Study, Multicenter Study
Sponsor: Mallinckrodt Ireland
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.